Tristetraprolin and its role in regulation of airway inflammation.

摘要: Chronic inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are clinically socioeconomically important diseases globally. Currently the mainstay of anti-inflammatory therapy in respiratory is corticosteroids. Although corticosteroids have proven clinical efficacy asthma, many asthmatic conditions (e.g., infection, exacerbation, severe asthma) not responsive to Moreover, despite an understanding that COPD progression driven by inflammation, we currently do effective strategies combat this disease. Hence, alternative required. p38 mitogen-activated protein kinase (MAPK) has emerged signaling molecule driving airway pharmacological inhibitors against MAPK may provide potential therapies for In review, discuss some recent vitro vivo studies targeting MAPK, but suggest prove less than originally considered because they block molecules along with proinflammatory responses. We propose strategy be target farther downstream i.e., tristetraprolin (TTP). TTP mRNA-destabilizing, RNA-binding enhances decay mRNAs, including those encoding proteins implicated diseases. molecular mechanism expression its temporal regulation will guide future development novel pharmacotherapeutic approaches